Canada Multiple Sclerosis Market Share,
Growth, Trends Report 2024
“These factors are expected to increase treatment
rates throughout the 10MM resulting, driving
market growth. However, this will be largely offset
by brand erosion due to the emergence of
biosimilars and generic small molecules.”
Summary
Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which
leads to neurological disability. The exact underlying cause of the disease is poorly understood;
however, it appears to involve a complex combination of genetic susceptibility and a non-genetic
trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available
treatment options. Over the forecast period, patients are expected to continue to switch to the oral
disease-modifying therapies (DMTs), lessening the stronghold of the established injectable
treatments. There are also several promising products in the late-stage pipeline, with a diverse
range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline
and marketed DMTs are seeking approval for the treatment of progressive MS, which currently
represents a significant unmet need. These factors are expected to increase treatment rates
throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand
erosion due to the emergence of biosimilars and generic small molecules.
Complete Report Available @ http://www.radiantinsights.com/research/multiple-
sclerosis-canada-drug-forecast-and-market-analysis-to-2024
Canada was the third-largest MS market in the 10MM in 2014, with DMT sales totaling $1.2 billion.
Steady growth is anticipated to occur between 2014 and 2020 as a result of novel pipeline agents
Follow Us: